ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Gene Expression"

  • Abstract Number: 1526 • ACR Convergence 2020

    Single Cell Analysis of Skin and Blood of Scleroderma Patients Towards Identification of New Disease Mechanisms, Prognostic Biomarkers and Potential Therapeutic Targets

    Chamutal Gur1, Postil 1586262, Hagit Peleg3, Suhail Aamar3, Fadi Kharouf3, Anat Elazary3, Yolanda Braun-Moscovici Braun-Moscovici4, Shuang-Yin Wang5 and Ido Amit5, 1Hadassah Medical Center, Hebrew University, Laboratory for Immuno-Genomics, Weizmann Institute of Science, Jerusalem, Israel, 2Rambam Health Care Campus, Technion-Israeli Institute of Technology, Kiriat Mozkin, HaZafon, Israel, 3Hadassah Medical Center, Jerusalem, Israel, 4Rambam Health Care Campus, Technion-Israeli Institute of Technology, Haifa, Israel, 5Laboratory for Immuno-Genomics, Weizmann Institute of Science, Rehovot, Israel

    Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis, microangiopathy and immune dysregulation. Despite many years of research, the pathogenesis of SSc is poorly understood; there…
  • Abstract Number: 0707 • ACR Convergence 2020

    Contribution of NOTUM and Glypicans to the Development of Osteoarthritis

    Arkaitz Mucientes1, Eva Herranz1, Pia Lois2, Gloria Candelas2, Lydia Abasolo1, Luis Rodriguez-Rodriguez1, Jose Ramon Lamas1 and Benjamin Fernandez-Gutierrez3, 1IdISSC, Madrid, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Madrid, Spain, 3Hospital Clínico San Carlos / IdISSC, Madrid, Madrid, Spain

    Background/Purpose: Osteoarthritis (OA) is a degenerative disease characterized by altered homeostasis of joint cartilage and bone, the functionality of which relies on chondrocytes and osteoblasts,…
  • Abstract Number: 1529 • ACR Convergence 2020

    Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients

    Noha Elemam1, Mahmood Hachim2, Suad Hannawi3 and Azzam Maghazachi4, 1University of Sharjah, Sharjah, United Arab Emirates, 2Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, 3Ministry of Health and Prevention, Dubai, United Arab Emirates, 4University of Sharjah, Sharjah

    Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells,…
  • Abstract Number: 0764 • ACR Convergence 2020

    Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data

    Dmitry Rychkov1, Jessica Neely1 and Marina Sirota1, 1UCSF, San Francisco, CA

    Background/Purpose: There is an urgent need to develop objective biomarkers for early diagnosis and monitoring of disease activity in Rheumatoid arthritis (RA). Here we define…
  • Abstract Number: 1611 • ACR Convergence 2020

    Documentation of Pregnancy Counseling in SSA-Positive Patients of Childbearing Potential: A Cross-Sectional Study

    Heinrich-Karl Greenblatt1 and Elena Weinstein1, 1University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Systemic lupus erythematosus (SLE) and primary Sjogren's Syndrome (SS) are highly associated with anti-SSA (anti-Ro) seropositivity. Anti-SSA autoantibodies may cross the placenta, causing a…
  • Abstract Number: 0866 • ACR Convergence 2020

    Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies

    Joan Merrill1, Matthew Studham2, Eric Morand3, Aida Aydemir2, Cristina Vazquez Mateo2, Alex Rolfe2, Amy Kao2 and Robert Townsend2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 3Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

    Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
  • Abstract Number: 1670 • ACR Convergence 2020

    Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset

    Fatima Barbar-Smiley1, Danlei Zhou2, Joanne Drew2, Bi Zhou2, Cagri Yildirim-Toruner2, Vidya Sivaraman3, Wael Jarjour4, Stacy Ardoin2 and Chack-Yung Yu5, 1Nationwide Children's Hospital/The Ohio State University, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital, Bexley, OH, 4The Ohio State University, Columbus, OH, 5Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: Hypocomplementemia is a marked feature of systemic lupus erythematosus (SLE), which may be a result of consumption initiated by immune complexes between self-nuclear antigens…
  • Abstract Number: 0969 • ACR Convergence 2020

    Investigating Murine Joint-Draining Lymphatics: Lineage Tracing and Single Cell RNA Sequencing Reveal Evidence That Popliteal Lymphatic Muscle Cells and Their Progenitors Represent Distinct Cell Types Divergent from Striated and Vascular Muscle Cells

    H. Mark Kenney1, Richard Bell2, Elysia Masters1, Lianping Xing1, Christopher Ritchlin3 and Edward Schwarz1, 1University of Rochester Medical Center, Rochester, 2Hospital for Special Surgery, New York, 3Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Previous studies demonstrated that tumor necrosis factor transgenic (TNF-Tg) mice with inflammatory arthritis have damaged lymphatic muscle cells (LMCs) and eventual loss of popliteal…
  • Abstract Number: 1850 • ACR Convergence 2020

    The Association Between Imaging Sub-phenotypes of Psoriatic Arthritis and Gene Expression Profiles

    Lihi Eder1, Lee Quan2, Sara Rahmati3, Iris Eshed4, Proton Rahman5, Igor Jurisica6 and Vinod Chandran7, 1Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, Canada, 3University Health Network, Toronto, ON, Canada, 4Sheba Medical Center, Tel-Aviv, Israel, 5Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 6Krembil RI, Toronto, Canada, 7Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Heterogeneity is a hallmark of psoriatic arthritis (PsA), which is reflected in diverse clinical, imaging and molecular features, various disease courses and treatment responses.…
  • Abstract Number: 0971 • ACR Convergence 2020

    Single-cell Profiling of Synovial Stromal Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis

    Kevin Wei1, Ilya Korsunsky2, Jennifer Marshall3, Gerald Watts4, Triin Major3, Zhu Zhu4, Yuhong Li5, Christopher Buckley6, Soumya Raychaudhuri7 and Michael Brenner1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, 4Brigam and Women's Hospital, Boston, 5Brigham and Women's Hospital, Boston, 6University of Birmingham, Birmingham, United Kingdom, 7Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Vascular endothelial cells that provide the structure for blood vessels have traditionally been perceived as passive, structural units that provide blood flow. We recently…
  • Abstract Number: 1910 • ACR Convergence 2020

    Integrated Molecular Analysis of Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major Autoantibody Subgroups

    Kristina Clark1, Corrado Campochiaro2, Eszter Csomor3, Adam Taylor3, Katherine Nevin3, Nicholas Galwey3, Mary Morse3, Voon Ong4, Emma Derrett-Smith5, Shaun Flint3 and Christopher Denton1, 1University College London, London, United Kingdom, 2Royal Free Hospital NHS trust, London, United Kingdom, 3GlaxoSmithKline, Stevenage, United Kingdom, 4UCL, London, United Kingdom, 5University College London Division of Medicine, London, United Kingdom

    Background/Purpose: The major antinuclear autoantibodies of systemic sclerosis (SSc) associate with different skin score trajectories and risk of internal organ manifestations.  To elucidate molecular differences…
  • Abstract Number: 1038 • ACR Convergence 2020

    STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis

    Marcia Friedman1, Brian Le2, Dongseok Choi2 and James Rosenbaum2, 1Oregon Health and Science University, Portland, OR, 2Oregon Health & Science University, Portland, OR

    Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
  • Abstract Number: 1911 • ACR Convergence 2020

    IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1

    Caya McFalls1 and Carol Artlett1, 1Drexel University College of Medicine, Philadelphia

    Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…
  • Abstract Number: 0032 • ACR Convergence 2020

    A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis

    Miklos Sebeszta1, Katalin Tauberne Jakab1, Tamas Ponyi1, Gyula Poor2, Zsolt Hollo1, Laszlo Szilagyi1, Emese Kiss2 and Gabor Zahuczky3, 1Egis Pharmaceuticals, Budapest, Hungary, 2ORFI, Budapest, Hungary, 3UD Genomed, Debrecen, Hungary

    Background/Purpose: Approximately 30-40% of RA patients fail to respond to first biological therapy. Predicting the patient’s responsiveness to the first biological therapy is still an…
  • Abstract Number: 1039 • ACR Convergence 2020

    Tofacitinib as a Steroid-sparing Therapy in Pulmonary Sarcoidosis: Two Prospective Cases and Molecular Analysis

    Marcia Friedman1, Stevens Janelle2, Julianna Desmarais3, Daniel Seifer3, Brian Le3, Kimberly Ogle3, Christina Harrington3, Peter Jackson4, Dongseok Choi3 and James Rosenbaum3, 1Oregon Health and Science University, Portland, OR, 2Tuality Healthcare, Hillsboro, OR, 3Oregon Health & Science University, Portland, OR, 4Johns Hopkins University, Baltimore, MD

    Background/Purpose: Patients with pulmonary sarcoidosis often require prolonged corticosteroids to treat their disease. There are currently no FDA approved steroid-sparing therapies for sarcoidosis. We report…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology